Amgen and AstraZeneca ponder label expansion for Tezspire in COPD
The companies plan to start Phase III trials for Tezspire in COPD despite missing the primary endpoint in the Phase IIb study.
The companies plan to start Phase III trials for Tezspire in COPD despite missing the primary endpoint in the Phase IIb study.
What's Your Reaction?
